Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from AFT Pharmaceuticals Ltd. ( (AU:AFP) ).
AFT Pharmaceuticals reported a robust financial performance for the first half of 2025, with a 33% revenue increase to $114.9 million, marking its 10th consecutive period of revenue growth. This growth was primarily driven by strong performances in Australia and a recovery in Asian and international markets. The company continues to advance its international business hubs and R&D portfolio, aiming for a $300 million revenue target by FY27. AFT’s strategic investments in licensing and development, including a novel IV iron formulation in China, position it for long-term growth and resilience.
More about AFT Pharmaceuticals Ltd.
AFT Pharmaceuticals Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of a broad range of pharmaceutical products. The company is known for its over-the-counter and prescription medicines, with a strong market presence in Australasia and expanding operations in international markets.
Average Trading Volume: 3,538
Technical Sentiment Signal: Hold
Current Market Cap: A$291.4M
For detailed information about AFP stock, go to TipRanks’ Stock Analysis page.